Kathryn Foucar – författare
Visar alla böcker från författaren Kathryn Foucar. Handla med fri frakt och snabb leverans.
2 produkter
2 produkter
3 192 kr
Skickas inom 5-8 vardagar
**Selected for 2025 Doody’s Core Titles� in Pathology**This expert volume in the Diagnostic Pathology series is an excellent point-of-care resource for practitioners at all levels of experience and training. Covering the full range of nonneoplastic and neoplastic conditions of blood and bone marrow, it incorporates the most recent scientific and technical knowledge in the field to provide a comprehensive overview of all key issues relevant to today’s practice. Richly illustrated and easy to use, the third edition of Diagnostic Pathology: Blood and Bone Marrow is a visually stunning, one-stop resource for every practicing pathologist, hematopathologist, oncologist, hematologist, resident, student, or fellow as an ideal day-to-day reference or as a reliable training resource.
2 327 kr
Skickas inom 11-20 vardagar
Evolution in the field of diagnostic hematopathology has been remarkable. The World Health Organization (WHO) classification scheme for hematologic neoplasms has achieved widespread endorsement and acceptance in clinical practice. This volume integrates proposed WHO 2016 recommendations and highlights areas in which further classification revisions may occur, or areas in which criteria are controversial. In addition, the immunophenotypic and molecular genetic tests of greatest value in diagnoses, risk assessment, and disease monitoring are highlighted in the text. The substantial focus on molecular genetic findings for each neoplasm parallels the ever-expanding role of genetics in disease classification and risk assessment.Key problem areas and differential diagnostic considerations are also included for each neoplastic disease category. Although primary blood and bone marrow neoplasms are the focus of this text, metastatic neoplasms in bone marrow are also covered.This atlas will provide readers with comprehensive information necessary for the clinical assessment of bone marrow neoplasms for years to come.